Researchers capture images of cells infected with SARS-CoV-2
Using scanning electron microscopy, researchers have captured images of epithelial cell cultures infected by SARS-CoV-2.
List view / Grid view
Using scanning electron microscopy, researchers have captured images of epithelial cell cultures infected by SARS-CoV-2.
Following their success in organoid systems, two drug candidates are now to be administered to ferrets and tested against COVID-19.
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
Researchers suggest possible therapies for macrophage activation syndrome (MAS), a feature of cytokine storm and a major cause of death in severe COVID-19 patients.
Professor Giovanni Di Guardo discusses the relationship between animals and humans in regards to the transmission of SARS-CoV-2.
In this NGS In-Depth Focus: how next-generation sequencing (NGS) enables rapid detection of viruses and a novel NGS platform advancing genomics research.
Researchers have found a nanobody named Ty1 that neutralises SARS-CoV-2 by attaching itself to the Spike protein of COVID-19.
A novel CRISPR system that suppresses genes related to adeno-associated virus (AAV) antibody production has been developed to prevent immunity against the gene therapy.
By analysing the expression of 28 genes, researchers have been able to identify which organs are most vulnerable to infection from COVID-19.
Researchers have developed a novel vaccine using nucleotide untranslated regions that successfully protected mice from COVID-19.
A genetic analysis of SARS-CoV-2 sequences reveal the virus has mutated minimally since December 2019, suggesting only one vaccine is needed to combat COVID-19.
The UK government will invest £8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.
Researchers have shown that factoring in valency to vaccine design can improve the number of antibody binding sites on an antigen.
Researchers reveal that activating the MHC class II transactivator (CIITA) and CD74 genes protected cells against infection by Ebola and SARS-CoV-2.
Scientists have patented their technique of inhibiting cellular growth factor signalling to stop SARS-CoV-2 replication and treat COVID-19.